Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Online reviews reveal troubling side effects of insomnia drug lemborexant (opens in a new tab)

news-medical.net · 2026-10-29

Short answerEvidenceSource

Short answer

Not supported

Not supported.

The study does not answer the story's main claims.

  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

The study doesn't address any of the story's claims. We found the paper, but it doesn't report the details the story leads with.

  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredResearchers from Rutgers and other universities analyzed hundreds of online reviews of lemborexant and found that about 1 in 4 reviewers stopped or planned to stop taking the prescription insomnia medication.View evidenceHide evidence

As statedabout 1 in 4

Why this verdict

The abstract-level profile supports that the paper analyzed 260 publicly available online reviews of lemborexant and examined intention to continue versus discontinue treatment. However, the abstract profile does not report the specific discontinuation/planned-discontinuation count or proportion of about 1 in 4, nor does it verify the author-affiliation framing. At abstract depth, the magnitude is not verifiable.

1

Study evidence

Approximately one third (30%) of respondents described meaningful improvements in sleep quality while half (50%) reported minimal or no perceived benefit.30% reported meaningful improvement; 50% reported minimal/no perceived benefit

“We conducted a mixed-methods infoveillance study analyzing publicly available user-generated online content describing experiences with lemborexant.”
2

Study evidence

Self-reported sleep paralysis, intensified oneiric phenomena (vivid dreams/nightmares), and next-day somnolence were reported as the themes most strongly associated with lower self-reported efficacy ratings and with intent to discontinue lemborexant.

“We examined how these themes were associated with self-reported efficacy ratings (1-10 scale) and intention to continue or discontinue treatment.”
Claim 2 of 4Not coveredIn the review sample, 70 of 260 reviewers were classified as having stopped or planning to stop, and side effects were what most clearly separated them from other reviewers.View evidenceHide evidence

As stated70 of 260

Why this verdict

The profile supports that coded adverse-experience themes were associated with intent to discontinue and that sleep paralysis, intensified oneiric phenomena, and next-day somnolence were the themes most strongly associated with lower ratings and discontinuation intent. But the exact 70-of-260 discontinuation/planned-discontinuation classification and the formulation that side effects 'most clearly separated' groups are not reported in the abstract-level evidence.

1

Study evidence

Approximately one third (30%) of respondents described meaningful improvements in sleep quality while half (50%) reported minimal or no perceived benefit.30% reported meaningful improvement; 50% reported minimal/no perceived benefit

“We conducted a mixed-methods infoveillance study analyzing publicly available user-generated online content describing experiences with lemborexant.”
2

Study evidence

Self-reported sleep paralysis, intensified oneiric phenomena (vivid dreams/nightmares), and next-day somnolence were reported as the themes most strongly associated with lower self-reported efficacy ratings and with intent to discontinue lemborexant.

“We examined how these themes were associated with self-reported efficacy ratings (1-10 scale) and intention to continue or discontinue treatment.”
Claim 3 of 4Not coveredSleep paralysis, vivid dreams or nightmares, and next-day grogginess were more common among people who stopped or planned to stop, with sleep paralysis mentioned in 40% of those reviews versus 15% of the rest.View evidenceHide evidence

As stated40% vs 15%

Why this verdict

The abstract-level profile supports the general association: sleep paralysis, intensified oneiric phenomena such as vivid dreams/nightmares, and next-day somnolence were most strongly associated with discontinuation intent. It does not provide the comparative frequencies claimed, including sleep paralysis in 40% of discontinuation/planned-discontinuation reviews versus 15% of the rest. The specific magnitude is therefore not verifiable at abstract depth.

1

Study evidence

Approximately one third (30%) of respondents described meaningful improvements in sleep quality while half (50%) reported minimal or no perceived benefit.30% reported meaningful improvement; 50% reported minimal/no perceived benefit

“We conducted a mixed-methods infoveillance study analyzing publicly available user-generated online content describing experiences with lemborexant.”
2

Study evidence

Self-reported sleep paralysis, intensified oneiric phenomena (vivid dreams/nightmares), and next-day somnolence were reported as the themes most strongly associated with lower self-reported efficacy ratings and with intent to discontinue lemborexant.

“We examined how these themes were associated with self-reported efficacy ratings (1-10 scale) and intention to continue or discontinue treatment.”
Claim 4 of 4Not coveredThe researchers said online reviews cannot show how common these experiences are among all users, and noted that in the drug's two main clinical trials fewer than 2 in 100 participants had sleep paralysis while about 1 to 3 in 100 reported nightmares or abnormal dreams.View evidenceHide evidence

As statedfewer than 2 in 100; about 1 to 3 in 100

Why this verdict

The profile supports the broad caveat that the evidence comes from publicly available user-generated online reviews, with representativeness and population-frequency inference limitations. It also notes that infoveillance may capture patient-centered experiences not fully represented in clinical trials. However, the abstract-level profile does not report the specific clinical-trial adverse-event rates for sleep paralysis, nightmares, or abnormal dreams, so the numerical trial comparison is not verifiable at this depth.

1

Study evidence

Approximately one third (30%) of respondents described meaningful improvements in sleep quality while half (50%) reported minimal or no perceived benefit.30% reported meaningful improvement; 50% reported minimal/no perceived benefit

“We conducted a mixed-methods infoveillance study analyzing publicly available user-generated online content describing experiences with lemborexant.”
2

Study evidence

Self-reported sleep paralysis, intensified oneiric phenomena (vivid dreams/nightmares), and next-day somnolence were reported as the themes most strongly associated with lower self-reported efficacy ratings and with intent to discontinue lemborexant.

“We examined how these themes were associated with self-reported efficacy ratings (1-10 scale) and intention to continue or discontinue treatment.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper’s central scope includes perceived effectiveness and treatment satisfaction, not only adverse effects or discontinuation.

    The abstract reports perceived benefit findings, including about 30% describing meaningful sleep improvement and 50% reporting minimal or no perceived benefit. The presented story summary and claims focus on discontinuation and side effects and do not reflect these effectiveness findings.

    From Mixed-methods infoveillance; reflexive thematic analysis

5 things the story did carry across
  • The paper is a mixed-methods infoveillance study of 260 publicly available online user reviews of lemborexant using reflexive thematic analysis.
  • Two-thirds of reviewers reported at least one adverse outcome, with exacerbated oneiric experiences such as vivid dreams or nightmares among the most frequent adverse outcomes.
  • Lower efficacy ratings and discontinuation intent were most strongly associated with self-reported sleep paralysis, intensified oneiric phenomena, and next-day somnolence.
  • Longer reported treatment duration was associated with higher perceived efficacy ratings.
  • The study’s evidence comes from publicly available, user-generated online reviews rather than controlled clinical assessments or a representative treated population.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataCharacterize real-world patient-reported perceived effectiveness, tolerability, and treatment satisfaction with lemborexant using publicly available online reviews.Mixed-methods infoveillance; reflexive thematic analysisExpand

In plain English

Mixed-methods infoveillance of 260 publicly available online patient reviews of lemborexant using reflexive thematic analysis to characterize perceived effectiveness, tolerability (including dream-related phenomena), and associations with self-reported efficacy ratings and intent to continue or discontinue treatment.

Key findings

  • Approximately one third (30%) of respondents described meaningful improvements in sleep quality while half (50%) reported minimal or no perceived benefit.30% reported meaningful improvement; 50% reported minimal/no perceived benefit
  • Two-thirds (68%) of respondents reported at least one adverse outcome; the most frequently reported were exacerbated oneiric experiences (vivid dreams or nightmares) and worsening of sleep quality.68% reported ≥1 adverse outcome
“We conducted a mixed-methods infoveillance study analyzing publicly available user-generated online content describing experiences with lemborexant.”
What this piece can’t prove
  • Analyses based on publicly available user-generated online reviews rather than controlled clinical assessments.

1 further detail could not be confirmed from the summary.

2secondary dataAssess associations between qualitative themes from online reviews and quantitative self-reported outcomes (efficacy ratings and intention to continue vs discontinue).mixed-methods association analysis of online reviewsExpand

In plain English

Within a mixed-methods infoveillance study of 260 publicly posted user reviews, the authors coded qualitative themes and tested associations between those themes and self-reported numeric efficacy ratings (1–10) and stated intent to continue versus discontinue lemborexant. Specific adverse-experience themes (sleep paralysis, intensified oneiric phenomena, and next-day somnolence) were reported as most strongly associated with lower efficacy ratings and with discontinuation intent; longer reported treatment duration was associated with higher perceived efficacy ratings. The abstract does not specify the statistical modeling procedures used for these association tests.

Key findings

  • Self-reported sleep paralysis, intensified oneiric phenomena (vivid dreams/nightmares), and next-day somnolence were reported as the themes most strongly associated with lower self-reported efficacy ratings and with intent to discontinue lemborexant.
  • Longer reported treatment duration was associated with higher perceived efficacy ratings.
“We examined how these themes were associated with self-reported efficacy ratings (1-10 scale) and intention to continue or discontinue treatment.”
What this piece can’t prove
  • Outcomes (efficacy ratings and continuation intent) are self-reported and derived from unsolicited online posts.
  • The abstract does not specify the statistical methods, effect sizes, or adjustments for potential confounders used in the theme–outcome association analyses.

1 further detail could not be confirmed from the summary.

3secondary dataExamine whether reported treatment duration is associated with perceived efficacy ratings in online reviews.Secondary data infoveillance (analysis of online user reviews)Expand

In plain English

Analysis of associations between self-reported treatment duration (from online user reviews) and perceived efficacy (self-rated 1–10) found that longer reported duration was associated with higher perceived efficacy ratings.

Key findings

  • Longer self-reported treatment duration in online reviews was associated with higher perceived efficacy ratings (self-rated 1–10).
“Longer treatment duration was associated with higher perceived efficacy ratings.”
What this piece can’t prove
  • Reliance on self-reported duration and efficacy from online reviews; measurement definitions and extraction methods not detailed in abstract.
  • Unknown whether analyses adjusted for potential confounders (e.g., baseline severity, concomitant treatments, demographics).
  • Potential selection bias of online reviewers and differential reporting of experiences.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Effects of lemborexant on chronic insomnia management in patients with COPD

Clinical and Epidemiological Respiratory Sleep Medicine · 2026 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.